Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cingulate Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CING
Nasdaq
8731
https://www.cingulate.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cingulate Inc
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
- Apr 29th, 2024 1:00 pm
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
- Apr 16th, 2024 9:00 pm
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Provides Clinical and Business Update
- Apr 1st, 2024 12:00 pm
Cingulate to Participate in Benzinga All Live Access Event
- Mar 19th, 2024 8:45 pm
Cingulate to Attend DCAT Week 2024 in New York City
- Mar 6th, 2024 11:45 am
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
- Feb 13th, 2024 11:45 am
Cingulate Announces Closing of $7.5 Million Public Offering
- Feb 6th, 2024 9:15 pm
Cingulate Announces Pricing of $7.5 Million Public Offering
- Feb 2nd, 2024 2:15 pm
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
- Jan 29th, 2024 1:00 pm
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
- Jan 29th, 2024 11:45 am
Why Is Cingulate (CING) Stock Up 160% Today?
- Dec 28th, 2023 3:15 pm
Midday movers: Microsoft, AMD, Boeing, and more
- Dec 28th, 2023 12:00 pm
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
- Dec 5th, 2023 12:00 pm
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
- Dec 1st, 2023 2:00 pm
Cingulate Inc. Reports Third Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update
- Nov 13th, 2023 9:15 pm
Cingulate to Host CNS Key Opinion Leader Panel in New York City
- Oct 17th, 2023 6:22 pm
Cingulate Inc. to Present at the LD Micro Main Event XVI
- Sep 21st, 2023 5:30 pm
Cingulate Announces Closing of $4.0 Million Public Offering
- Sep 13th, 2023 8:15 pm
Cingulate Announces Pricing of $4.0 Million Public Offering
- Sep 11th, 2023 1:22 pm
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
- Sep 8th, 2023 8:31 pm
Scroll